PMID- 11706965
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20191025
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 50
IP  - 5
DP  - 2001 Nov
TI  - Sexual dimorphism and developmental regulation of substantia nigra function.
PG  - 596-601
AB  - The substantia nigra is an important brain nucleus involved in the expression of 
      movement disorders and seizures. The two most common movement disorders affecting 
      the substantia nigra, Parkinson's disease and Tourette syndrome, show gender 
      differences and age-related onset. To assess the substrates for the gender and 
      age specificity of substantia nigra-related disorders, we determined the 
      functional properties of the substantia nigra gamma-aminobutyric acid (GABAA) 
      system along its anterior-posterior axis, using localized microinfusions of 
      muscimol (a GABAA agonist) and susceptibility to motor seizures in rats. In the 
      substantia nigra, there are sex-specific differences in the topographic 
      segregation and functionality of GABAA systems. In mature male rats there are two 
      distinct regions mediating opposite effects on seizures; in female rats there is 
      only one region that can affect seizures. In the neonatal period, the presence of 
      circulating testosterone is essential for the development of a substantia nigra 
      region that exerts proconvulsant effects throughout the rat's life, a unique 
      feature of the male substantia nigra. The final maturation of the substantia 
      nigra occurs in the peripubertal period, and is in part regulated by testosterone 
      as well. The recognition of the existence of distinct sex- and age-specific 
      substantia nigra features can be translated into new cures of disorders affecting 
      the substantia nigra.
FAU - Veliskova, J
AU  - Veliskova J
AD  - Department of Neurology, and Montefiore/Einstein Epilepsy Management Center, 
      Albert Einstein College of Medicine, Bronx, NY 10461, USA. velisek@aecom.yu.edu
FAU - Moshe, S L
AU  - Moshe SL
LA  - eng
GR  - NS-20253/NS/NINDS NIH HHS/United States
GR  - NS-36238/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 0 (Convulsants)
RN  - 0 (GABA Agonists)
RN  - 2763-96-4 (Muscimol)
RN  - 3XMK78S47O (Testosterone)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
SB  - IM
MH  - Aging/*physiology
MH  - Animals
MH  - Animals, Newborn
MH  - Castration
MH  - Convulsants
MH  - Disease Susceptibility
MH  - Female
MH  - GABA Agonists/pharmacology
MH  - Male
MH  - Microinjections
MH  - Muscimol/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Seizures/chemically induced/physiopathology
MH  - *Sex Characteristics
MH  - Sex Factors
MH  - Substantia Nigra/*growth & development/*physiology
MH  - Testosterone/blood/pharmacology
MH  - gamma-Aminobutyric Acid/metabolism
EDAT- 2001/11/15 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/15 10:00
PHST- 2001/11/15 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/15 10:00 [entrez]
AID - 10.1002/ana.1248 [doi]
PST - ppublish
SO  - Ann Neurol. 2001 Nov;50(5):596-601. doi: 10.1002/ana.1248.